Real-world experience of venetoclax for patients with newly diagnosed acute myeloid leukemia in Japan: a Multicenter Observational Study

Real-world experience of venetoclax for patients with newly diagnosed acute myeloid leukemia in Japan: a Multicenter Observational Study - VENUS study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050247

Enrollment

100

Registered

2023-02-06

Start date

2023-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients aged 18 or older at the time of conducting the study. 2.Patients newly diagnosed with Intensive chemotherapy ineligible AML and treated with VEN plus AZA or low-dose Ara-C (LDAC). 3. Patients who started treatment with VEN between June 23, 2021 and September 30, 2022.

Exclusion criteria

Exclusion criteria: 1.Patients who explicitly declines the use of data for this study. 2.Patients who received prior lines of therapy for AML. (Note that patients treated with AZA for MDS will be included in this study)

Design outcomes

Primary

Measure	Time frame
Primary outcome 1.Overall survival (OS)	—

Secondary

Measure	Time frame
Secondary outcome: 1.Event-free survival (EFS) 2.Response rate, time to first response, duration of response (DoR) 3.Time course of blood cell counts 4.Healthcare resource utilization (transfusion, supportive care, hospitalization/outpatient visits) 5.Treatment patterns	—

Countries

Japan

Contacts

Public ContactMizuha Kanaya

AbbVie GK Oncology, Medical Affairs, Medical

mizuha.kanaya@abbvie.com03-4577-1111

Outcome results